Free Publication in 2018
Free Publication in 2018
Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
New and Old Therapeutic Options for Crohn’s Disease
Submission Deadline: January 31, 2019 (Open) Submit Now
Tony C. K. Tham, MD, MB BCh BAO, MSc, FRCP, FRCPI
About This Topic
There are currently four biologic therapies available for Crohn’s disease and many new therapeutic options such as small molecules in the development pipeline. There are also currently other well established drugs such as thiopurines, methotrexate, budesonide and steroids for the treatment of Crohn’s. In addition, other therapeutic options include surgery, endoscopic therapy and dietary intervention. This special issue seeks submissions that address the role of these treatment options for the management of Crohn’s, how these options can be used in treatment pathways, how these therapies can be combined to best effect, and how to select the right patient for the right intervention. The submissions can be in the form of review articles, opinions or original research. We would like to invite you to submit your work for consideration of publication in this special issue.
Title: Managing Fatty Liver Disease in the Inflammatory Bowel Disease Patient